CIA
CGEM icon

Compass Ion Advisors’s Cullinan Oncology CGEM Stock Holding History

Compass Ion Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,904
Closed -$144K – 281
2025
Q4 		$144K Hold
13,904
– – 0.01% 271
2025
Q3 		$82.5K Buy
+13,904
New +$102K 0.01% 274

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Compass Ion Advisors's CGEM Position: Q1 2026 in Review

Compass Ion Advisors sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 13,904 shares — an estimated $144K sold.

Compass Ion Advisors first reported a position in CGEM in Q3 2025 and held it in 2 quarters. The position peaked at $144K in Q4 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Compass Ion Advisors reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Compass Ion Advisors sold 13,904 Cullinan Oncology shares in Q1 2026, an estimated $144K.
  • Compass Ion Advisors first reported a position in Cullinan Oncology in Q3 2025 and held it in 2 quarters.
  • Compass Ion Advisors's Cullinan Oncology position peaked at $144K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Compass Ion Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.